Format

Send to

Choose Destination
EBioMedicine. 2019 Mar 21. pii: S2352-3964(19)30149-5. doi: 10.1016/j.ebiom.2019.03.009. [Epub ahead of print]

Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning.

Author information

1
Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm SE-17121, Sweden; Department of Bioengineering, Marmara University, Istanbul, Turkey; Department of Bioengineering, Istanbul Medeniyet University, Istanbul, Turkey.
2
Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm SE-17121, Sweden.
3
Department of Bioengineering, Marmara University, Istanbul, Turkey. Electronic address: kazim.arga@marmara.edu.tr.
4
Science for Life Laboratory, KTH - Royal Institute of Technology, Stockholm SE-17121, Sweden; Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg SE-41296, Sweden; Centre for Host-Microbiome Interactions, Faculty of Dentistry, Oral & Craniofacial Sciences, King's College London, London, United Kingdom. Electronic address: adilm@scilifelab.se.

Abstract

BACKGROUND:

Genome-scale metabolic models (GEMs) offer insights into cancer metabolism and have been used to identify potential biomarkers and drug targets. Drug repositioning is a time- and cost-effective method of drug discovery that can be applied together with GEMs for effective cancer treatment.

METHODS:

In this study, we reconstruct a prostate cancer (PRAD)-specific GEM for exploring prostate cancer metabolism and also repurposing new therapeutic agents that can be used in development of effective cancer treatment. We integrate global gene expression profiling of cell lines with >1000 different drugs through the use of prostate cancer GEM and predict possible drug-gene interactions.

FINDINGS:

We identify the key reactions with altered fluxes based on the gene expression changes and predict the potential drug effect in prostate cancer treatment. We find that sulfamethoxypyridazine, azlocillin, hydroflumethiazide, and ifenprodil can be repurposed for the treatment of prostate cancer based on an in silico cell viability assay. Finally, we validate the effect of ifenprodil using an in vitro cell assay and show its inhibitory effect on a prostate cancer cell line.

INTERPRETATION:

Our approach demonstate how GEMs can be used to predict therapeutic agents for cancer treatment based on drug repositioning. Besides, it paved a way and shed a light on the applicability of computational models to real-world biomedical or pharmaceutical problems.

KEYWORDS:

Approved drugs; Drug repositioning; Drug repurposing; Genome-scale metabolic models; Prostate cancer

PMID:
30905848
DOI:
10.1016/j.ebiom.2019.03.009
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center